Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Perspective

Enhancing preparation for large Nipah outbreaks beyond Bangladesh: Preventing a tragedy like Ebola in West Africa

Halsie Donaldson, Daniel Lucey*

Department of Medicine-Infectious Diseases, Georgetown University School of Medicine, 3800 Reservoir Road NW, Washington, DC, USA

ABSTRACT

The Nipah virus has been transmitted from person-to-person via close contact in non-urban parts of India (including Kerala May 2018), Bangladesh, and the Philippines. It can cause encephalitis and pneumonia, and has a high case fatality rate. Nipah is a One Health zoonotic infectious disease linked to fruit bats, and sometimes pigs or horses. We advocate anticipating and preparing for urban and larger rural outbreaks of Nipah. Immediate enhanced preparations would include standardized guidance on infection prevention and control, and personal protective equipment, from the World Health Organization (WHO) on their OpenWHO website and 2018 "Managing Epidemics" handbook, along with adding best clinical practices by experts in countries with multiple outbreaks such as Bangladesh and India. Longer-term enhanced preparations include accelerating development of field diagnostics, antiviral drugs, immune-based therapies, and vaccines. WHO-coordinated multi-partner protocols to test investigational treatments, diagnostics, and vaccines are needed, by analogy to such protocols for Ebola during the unanticipated pan-epidemic in Guinea, Liberia, and Sierra Leone. Anticipating and preparing now for urban and rural Nipah outbreaks in nations with no experience with Nipah will help avoid the potential for what the United Nations 2016 report on Ebola in West Africa called a “preventable tragedy”.

© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Nipah virus, within the family Paramyxoviridae (Wang et al., 2001), was first identified in humans with encephalitis in the 1998–1999 outbreak in Malaysia and Singapore, involving at least 276 cases and 106 deaths (Chua et al., 2000). The epidemiological link was from fruit bats infecting pigs that then served as an amplifier host and infected humans through close contact. Person-to-person transmission was rarely documented, and no further human cases have been reported from either country. Detailed analyses of the environmental changes that triggered this outbreak connecting wildlife (bats), livestock (pigs), and humans were reported (Pulliam et al., 2012; Daszak et al., 2013). This triad of human, animal, and environmental health (One Health) makes Nipah virus outbreaks a prime example of what we have termed the associated pan-epidemic Anthropocene (Lucey et al., 2017).

Nipah virus outbreaks, with person-to-person transmission, have occurred repeatedly in rural Bangladesh. In addition, a nosocomial outbreak involving over 60 people in a hospital in Siliguri, West Bengal, India in 2001 was recognized retrospectively (Chadha et al., 2006). In 2007, a smaller outbreak occurred in West Bengal, again with person-to-person transmission (Arankalle et al., 2011). Antibody to Nipah virus was found in 2003 in Pteropus giganteus fruit bats in Haryana State in northern India (Epstein et al., 2008). Subsequent outbreaks in Bangladesh have been documented during winter months over the past 16 years, associated with the consumption by humans of date palm sap (or occasionally a liquor from date palm sap) contaminated with Nipah virus from the urine or saliva of fruit bats (Hegde et al., 2016; Cortes et al., 2018). Pigs do not appear to play a role in human infections in Bangladesh or India.

Unlike in Malaysia and Singapore, however, person-to-person transmission of Nipah virus has repeatedly been documented in Bangladesh. For example, in a 2004 outbreak, ‘patient F’ transmitted to 22 persons (Gurley et al., 2007). Most such human-to-human transmission has been linked to close contact, and primarily from a small percentage of infected persons. For

* Corresponding author.
E-mail address: DRL23@Georgetown.edu (D. Lucey).
example, 62 of 122 persons (51%) with Nipah infection in Bangladesh in 2001–2007 became ill after close contact with another person with Nipah. A possible role for respiratory secretions in transmission has been suggested, because patients with Nipah in Bangladesh have often had pneumonia as well as encephalitis (Hossain et al., 2008), and viral RNA has frequently been identified in respiratory/oral swabs (Hassan et al., 2018). Of note, only nine of these 62 persons (7%) from the years 2001–2007 appeared to be responsible for transmitting the virus from person to person (Luby et al., 2009a,b). The overall case-fatality rate has been estimated by the World Health Organization (WHO) to be approximately 75% (WHO/SEARO, 2001–2012).

A ‘Nipah belt’ has been described across the western part of Bangladesh (Hahn et al., 2014). Notably, human cases have not been reported from outbreaks in the capital city of Dhaka or other major urban areas. Importantly, however, Epstein and colleagues recently reported that Nipah virus RNA in bats exists throughout much of Bangladesh, even beyond the Nipah belt. They noted: “NIV detection was not restricted to the Nipah belt, suggesting spillover is possible anywhere in Bangladesh if a suitable strain and bat–human interface were present” (Epstein et al., 2016). Taken together, it is anticipated that the risk of undetected outbreaks of Nipah in Bangladesh and elsewhere in Asia, due either to infected travelers or transmission from bats to humans with associated person-to-person transmission, should be actively anticipated and actions taken in recognition of this threat.

For example, while this manuscript was being revised, the first-ever Nipah outbreak in southern India was reported on May 21, 2018 in Kerala. Laboratory confirmation of Nipah virus infection in family and community members and healthcare workers consistent with person-to-person transmission has been reported as of May 24, 2018. The WHO Southeast Asia Regional Office (SEARO) update as of May 24 reported 14 laboratory-confirmed cases, with 12 deaths and 20 suspected cases. The interim assessment by SEARO was that this “is not a major outbreak. It is only a local occurrence”. The source of infection was assumed to be fruit bats, although laboratory and epidemiological investigations are ongoing (WHO/SEARO, May 24, 2018).

Much larger outbreaks of Nipah, both rural and urban, should be anticipated, especially in nations lacking the experience with Nipah of Bangladesh, Malaysia, and India, e.g., Myanmar, Indonesia, and other nations in Asia, the Middle East, and Africa. Preparations for Nipah outbreaks should be enhanced in order to avoid the unanticipated ‘preventable tragedy’ of the urban and rural Ebola pan-epidemics in 2014 in West Africa (United Nations Report, 2016) that resulted in over 28 000 persons reported with Ebola virus disease, of whom over 11 000 died. Likely many other deaths occurred during the Ebola pan-epidemics due to the unavailability of what healthcare systems existed before Ebola emerged. In 2013, Luby discussed “the pandemic potential of Nipah” (Luby, 2013). We concur and re-emphasize the call to action in 2018, especially for Nipah epidemics in nations with no prior experience with Nipah, by analogy to West Africa and Ebola in 2013–2016.

Similarly, the urban pneumonia plague (UPP) epidemic in Madagascar in 2017, with approximately 2025 persons diagnosed with plague pneumonia (WHO AFRO, 2018), termed afterwards a “tragic opportunity for improving public health” (Mead, 2018), was unanticipated in terms of needed preparedness measures.

Either urban or rural outbreaks of Nipah should be prepared for wherever the bat host and virus occur, not only in Bangladesh, but at least in parts of India (e.g., now in Kerala as well as West Bengal), Malaysia, Singapore, Indonesia, and also in Thailand and the Philippines. In southern Thailand, Nipah virus has been found in bats; however, no human infections have been documented. Sequencing of the N gene (1599 bp) from this Nipah virus showed 99.1–99.4% identity with the Malaysian strain of Nipah (Wacharapluesadee et al., 2016).

**Human outbreak of Nipah or a Nipah-like virus involving horses in the Philippines, 2014**

In 2014, an outbreak of a Nipah virus (or very closely related henipavirus) occurred in two villages in Mindanao in the southern Philippines. Of the 17 persons who met the case definition, 11 had acute encephalitis, one meningitis, and five an influenza-like illness. Unlike the outbreak in Malaysia in 1998–1999 or the pan-epidemics in Bangladesh, this outbreak in Mindanao appeared to involve horses transmitting the virus to humans. Of the 17 cases, seven had been involved with horse slaughtering or horse meat consumption and five had provided care to other patients either in the hospital, during transportation to the hospital, or in the home. At least 10 horses died, including nine that had an acute neurological illness (Ching et al., 2015).

Laboratory testing of three case patients revealed both neutralizing antibodies against Nipah virus and IgM antibodies consistent with recent Nipah virus infection. Real-time PCR on serum from one patient was positive for Nipah virus. The spinal fluid of a second patient was found to have a single sequence read (71 bp) of the P gene of Nipah virus. This short sequence had 99.6% identity with Nipah virus isolates from Malaysia (and 94–96% identity with isolates from Bangladesh) (Ching et al., 2015).

Of note, horses in Australia have been linked to infection with Hendra virus, a henipavirus like Nipah. Hendra virus, discovered in 1994, has not been reported to be transmitted person to person (Queensland Government, 2016.), unlike this Nipah or Nipah-like virus in the Philippines. The only previous reported link between Nipah viruses and horses been with two polo ponies that were reported to be infected with Nipah virus in the Malaysia 1998–1999 epidemic (Chua et al., 2000).

Separate from any naturally-occurring Nipah virus outbreaks, intentional release of Nipah virus has also been recognized as a potential risk. The initial October 2015 publication of the US “Bipartisan Report of the Blue Ribbon Study Panel on Biodefense” included a brief scenario of a hypothetical attack in Washington, DC, and in other locations in the USA and abroad that was due to a ‘genetically modified’ and aerosolized Nipah virus. The zoonotic or ‘One Health’ nature of human infections with Nipah virus was recognized in this scenario, with animal deaths occurring as well as human fatalities. Notably, of the 34 recommendations from this Blue Ribbon panel, recommendation number 7 was to “integrate animal health and One Health approaches into biodefense strategies” (Lieberman and Ridge, 2015). Similarly, on May 15, 2018 an all-day large simulation exercise called ‘Clade X’ was carried out and posted online (Johns Hopkins Center for Health Security). The hypothetical pathogen was a bioengineered transmissible hybrid virus with genes from Nipah virus and human parainfluenza virus. Intentional attacks began in Caracas, Venezuela and in Frankfurt, Germany and then spread to over 300 cities via international travel.

**Enhancing preparedness for large rural and urban Nipah virus outbreaks**

In January 2017, and again in February 2018, the WHO included Nipah and related henipaviral diseases on its list of priority diseases for investment in research and development for diagnostics, prevention, and treatments (WHO, 2016a). In a related announcement in January 2017, Nipah virus was listed as one of three viruses (along with Lassa virus and Middle East respiratory syndrome coronavirus (MERS-CoV)) that would be prioritized by the new Coalition for Epidemic Preparedness Innovations (CEPI).
for vaccine development (Rotttingen et al., 2017). Currently there are no US Food and Drug Administration (FDA)-licensed Nipah vaccines, antiviral drugs, or immunotherapies for humans, although candidates exist in the early stages of development (Broder et al., 2016; Satterfield et al., 2016).

At least one person in the USA who had a high-risk laboratory exposure to Nipah virus has received the experimental neutralizing monoclonal antibody (termed m102.4) against the Nipah viral glycoprotein G, on an emergency use basis (Broder et al., 2016). In Australia, an equine vaccine against the closely-related Hendra henipavirus to prevent infection in horses has been licensed since 2015 (Broder et al., 2016).

Enhancement of preparedness measures for future urban Nipah outbreaks should include heightened surveillance, coordinated rapid diagnostic testing, training exercises including the use of and sufficient supplies of personal protective equipment (PPE), detailed isolation and quarantine protocols, clinical management protocols, and discussion of research protocols and their ethics for use of investigative therapies and vaccines. As with Ebola, Nipah virus has been reported to occur in healthcare facilities, including infection of health workers, and at burials from an infected corpse (Sazzad et al., 2013).

The timelines should be accelerated to develop not only vaccines but also immune-based antibody therapies and antiviral drugs (Bosserart et al., 2012; Broder et al., 2013; Geisbert et al., 2014; Elshabrawy et al., 2014; Satterfield et al., 2016; Rotttingen et al., 2017). Prior to the Ebola pan-epidemic in West Africa there were only unlicensed, early-stage candidate Ebola vaccines, immune-based antibodies, and potential antiviral drugs, as is the case today for these three types of Nipah virus countermeasure in humans.

Importantly, in 2011 Bangladesh provided a detailed protocol (Rahman and Husain, 2011) on national guidelines for the fundamental issues of clinical management, prevention and control of Nipah virus infection. Such national leadership, from the nation with the most experience with Nipah virus outbreaks, should be incorporated further into international guidelines and preparedness mechanisms, for example by the WHO. As of May 27, 2018, the recently developed WHO Open online course modules (WHO, 2018b) for many diseases and epidemic-related topics do not include a teaching module for Nipah virus (WHO Open; https://openwho.org/courses). This gap can readily be closed by collaboration with Nipah experts from Bangladesh, India (especially now from Kerala) and elsewhere. Similarly, the 2018 WHO handbook “Managing Epidemics” on 15 deadly diseases does not include Nipah; however, it could readily be added to provide essential clinical and infection prevention and control information (WHO, 2018c).

In conclusion, we emphasize the increasing geographic range and expanding epidemiological patterns of Nipah virus in Asia and the potential for urban outbreaks to occur in the near future. Similar to the situation with Ebola in West Africa, there are no licensed vaccines, antiviral drugs, or immune-based antibody therapies for Nipah virus, although early-stage investigational candidates exist for all three types of countermeasure. Unlike before the pan-epidemics of Ebola in West Africa 2014–2016, anticipating urban Nipah virus epidemics and also taking the comprehensive actions needed to prepare for and mitigate such epidemics is still possible in 2018 to avoid disasters like the “preventable tragedy of Ebola” in West Africa (United Nations Report, 2016).

**Funding source**

No funding source; no study sponsor.

**Ethical approval**

Approval was not required.

**Conflict of interest**

No conflict of interest.

**References**

Arankalle V, Bandyopadhyay B, Ramdasi A, Jadi R, Patil D, Rahman M, et al. Genomic characterization of Nipah virus, West Bengal, India. Emerg Infect Dis 2011;17 (5):907–9.

Bosserart K, Rockx B, Feldmann F, et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 2012;4:1–8 146ra107.

Broder C, Xu K, Nikolov D, Zhu Z, Dimitrov DS, Middleton D, et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res 2013;100(1) 8–13. [Accessed 6 February 2018] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418552.

Broder C, Weir D, Reid P. Hendra virus and Nipah virus animal vaccines. Vaccine 2016;34(30):3525–34.

Chadha MS, Corner JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis 2006;12 (February) (2):235–40.

Ching P, Carr de los Reyes, Sucaldito M, Tayaga E, Columna-Viongno A, Malbas F, et al. Outbreak of henipavirus infection, Philippines, 2014. Emerg Infect Dis 2015;21 (February) :328–31.

Chua KB, Bellini WJ, Rota P, Harcourt B, Tamin A, Lam S, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000;288:1432–5.

Cortes MC, Cauchemez S, Lefauq N, Luby S, Jahangir HM, Sazzad HHS, et al. Characterization of the spatial and temporal distribution of Nipah virus spillover events in Bangladesh, 2007–2013. J Infect Dis 2018;217(9):1390–4.

Daszak P, Zambrano-Torrello Carlos, Bogich Tiffany L, Fernandez Miguel, Epstein Jonathan H, Murray Kris A, et al. Interdisciplinary approaches to understanding disease emergence: the past, present, and future drivers of Nipah virus emergence. PANAS 2011; 130 Suppl 1:3681–8.

Elshabrawy H, Fan J, Haddad C, Katia R, Broder C, Caffrey M, et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J Virol 2014;88(8):4353–65.

Epstein J, Prakash V, Smith C, Daszak P, McLaughlin A, Meehan G, et al. Henipavirus infection in fruit bats (Pteropus giganteus). India. Emerg Infect Dis 2008;14 (8):1309–11.

Epstein J, Anthony S, Islam A, Kilpatrick A, Khan A, Ross N, et al. Nipah virus ecology and infection dynamics in its bat reservoir, Pteropus medius, in Bangladesh. Int J Infect Dis 2016;53(Suppl):20–1.

Geisbert T, Mire C, Geisbert J, Chan Y-P, Agans K, Feldmann F, et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody, Sci Transl Med 2014;6(242), doi:http://dx.doi.org/ 10.1126/scitranslmed.3008592.

Guerrly E, Montgomery J, Hossain M, Bell M, Azad A, Islam M, et al. Person to person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 2008;13:1031–7.

Hahn M, Guerrly E, Epstein J, Islam M, Patz J, Daszak P, et al. The role of landscape composition and configuration on Pteropus giganteus roosting ecology and Nipah virus spillover in Bangladesh. Am J Trop Med Hyg 2014;90(2):247–55.

Hassan MZ, Sazzad H, Luby S, Sturm-Ramirez K, Bhuiany M, Rahman M, et al. Nipah virus contamination of hospital surfaces during outbreaks, Bangladesh, 2013-2014. Emerg Infect Dis 2018;24(January) (1). doi:http://dx.doi.org/10.3201/ eid2401.160758.

Hegesh S, Sazzad H, Hossain M, Alam M-U, Renah E, Dazak P, et al. Investigating rare risk factors for Nipah virus in Bangladesh 2001–2012. EcoHealth 2016;14 (4):720–8.

Hossain M, Guerrly E, Montgomery J, Bell M, Carroll D, Hsu V, et al. Clinical presentation of nipah virus infection in Bangladesh. Clin Infect Dis 2008;46:977–84.

Johns Hopkins Center for Health Security. Clade X exercise. http://www.centerforhealthsecurity.org/our-work/events/2018/clade-x_exercise/. [Accessed 27 March 2018].

Lieberman J, Ridge T. A national blueprint for biodefense. Bipartisan report of the Blue Ribbon study panel on biodefense. 2015 October. https://www.ecohealth-alliance.org/wp-content/uploads/2016/03/R-National-Blueprint-for-Biodefense-October2015.pdf. [Accessed 17 January 2018].

Luby S, Hossain J, Guerrly E, Ahmed B-N, Banu S, Khan S, et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001–2007. Emerg Infect Dis 2009a;15:1229–35.

Luby S, Guerrly E, Hossain M. Transmission of human infection with Nipah virus. CID 2009b;49:1743–8.

Luby S. The pandemic potential of Nipah virus. Antiviral Res 2013;100:38–43.

Lucey D, Sholleis S, Donaldson H, et al. One health education for future physicians in the pan-epidemic “Age of Humans”. Int J Infect Dis 2017;64:1–3.
Mead P. Plague in Madagascar—a tragic opportunity for improving public health. N Engl J Med 2018;378(January):106–8. http://www.nejm.org/doi/full/10.1056/NEJMp1713881?af=R&rss=currentIssue#t=article.

Pulliam J, Epstein J, Diehoff J, et al. Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis. J R Soc Interface 2012;9:89–101.

Queensland Government 2016. https://www.business.qld.gov.au/industries/farms-fishing-forestry/agriculture/livestock/animal-welfare/pests-diseases-disorders/hendra-virus. [Accessed 17 January 2018].

Rahman M, Husain M. National guideline for management, prevention, and control of nipah virus infection including encephalitis. 2011. http://www.iedcr.gov.bd/pdf/files/nipah/National_Nipah.pdf.

Rottingen J-A, Gouglas D, Feinberg M, Plotkin S, Feinberg M, et al. New vaccines against epidemic infectious diseases. N Engl J Med 2017;376:610–3.

Satterfield B, Dawes B, Milligan G. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 2016;34:2971–5.

Sazzad H, Hossain M, Gurley E, Ameen KM, Parveen S, Islam MS, et al. Nipah virus infection outbreak with nosocomial and corpse-human transmission, Bangladesh. Emerg Infect Dis 2013;19(2):210–7.

WHO/SEARO. Nipah viruses outbreaks in the WHO South-East Asia Region (SEARO). http://www.searo.who.int/entity/emerging_diseases/links/nipah_virus-outbreaks_sear/en/. [Accessed 19 June 2018].

WHO/SEARO. Update on Nipah outbreak in Kerala, India. http://www.searo.who.int/india/topics/emergencies/mohfw-niv-press-release-24may2018.pdf. [Accessed 27 May 2018].

United Nations. Protecting humanity from future health crises. January 2016. http://www.un.org/News/dh/infocus/HLP/2016-02-05_Final_Report_Global_Response_to_Health_Crises.pdf. [Accessed 18 January 2018].

Wacharapluesadee S, Samseeneam P, Pherrmpool M, Kaewpam T, Rodpan A, Maneenorn P, et al. Molecular characterization of Nipah virus from Pteropus hypomelanus in Southern Thailand. Virol J 2016;13:53.

Wang L-F, Harcourt B, Yu M, Tamin A, Rota P, Bellini W, et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001;3:279–87.

WHO. List of blueprint priority diseases. http://www.who.int/blueprint/priority-diseases/en/. February 6-7, 2018. [Accessed 4 March 2018].

WHO Open online course modules. https://openwho.org/courses. [Accessed 4 March 2018].

WHO. Managing epidemics: key facts about major deadly diseases. 2018 (May). 255 Pages. http://www.who.int/emergencies/diseases/managing-epidemics/en/. [Accessed May 21, 2018].

WHO AFRO. Weekly bulletin on outbreaks and other emergencies, February 26, 2018. http://www.afro.who.int/health-topics/disease-outbreaks/outbreaks-and-other-emergencies.updates. [Accessed 4 March 2018].